The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)

被引:37
作者
Morgante, Francesca [1 ,2 ,3 ,4 ]
Bavikatte, Ganesh [5 ]
Anwar, Fahim [6 ]
Mohamed, Biju [7 ]
机构
[1] St Georges Univ London, Neurosci Res Ctr, Mol & Clin Sci Res Inst, London, England
[2] Univ Messina, Dept Expt & Clin Med, Messina, Italy
[3] St Georges Univ London, Mol & Clin Sci Res Inst, London, England
[4] Cranmer Terrace,Jenner Wing,Ground Floor, London SW17 0RE, England
[5] Walton Ctr NHS Fdn Trust, Dept Rehabil Med, Liverpool, Merseyside, England
[6] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Dept Rehabil Med, Cambridge, England
[7] Univ Hosp Wales, Dept Med & Gerontol, Cardiff, S Glam, Wales
关键词
sialorrhoea; botulinum toxin; incobotulinumtoxinA; Parkinson's disease; Motor; neuron disease; AMYOTROPHIC-LATERAL-SCLEROSIS; BOTULINUM-TOXIN-A; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; MOTOR-NEURON DISEASE; PARKINSONS-DISEASE; DOUBLE-BLIND; CEREBRAL-PALSY; NONINVASIVE VENTILATION; ANTICHOLINERGIC BURDEN;
D O I
10.1177/1756286419888601
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson's disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and their caregivers, the impact of which can be both physical and psychosocial. Treatments for sialorrhoea range from lifestyle and behavioural guidance, to medications, surgery or radiation. Nonpharmacological interventions include advice on posture, swallowing control, cough management, dietary changes, eating and drinking techniques, and behavioural modification; however, these conservative measures may be ineffective for people with progressive neurological conditions. The pharmacological treatment of sialorrhoea is challenging because medications licensed for this purpose are limited, but treatments can include anticholinergic drugs and botulinum toxins. Surgical treatment of sialorrhoea is typically reserved as a last resort for patients. IncobotulinumtoxinA (Xeomin (R)) is the first botulinum toxin type A to receive US and UK marketing authorization for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults. In this review, we discuss and compare the frequency and method of administration, location of treatment delivery, approximate annual costs and main side effects of botulinum toxin and different anticholinergic drugs. Management of patients with chronic neurological conditions requires input from multiple specialist teams and thus a multidisciplinary team (MDT) approach is considered fundamental to ensure that care is consistent and tailored to patients' needs. To ensure that adult patients with neurological conditions receive the best care and sialorrhoea is well managed, we suggest a potential clinical care pathway for sialorrhoea with a MDT approach, which healthcare professionals could aspire to.
引用
收藏
页数:21
相关论文
共 131 条
[1]  
Aging Brain Program, 2008, ANT COGN BURD SCAL 2
[2]   High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy [J].
Albrecht, Philipp ;
Jansen, Alexander ;
Lee, John-Ih ;
Moll, Marek ;
Ringelstein, Marius ;
Rosenthal, Dietmar ;
Bigalke, Hans ;
Aktas, Orhan ;
Hartung, Hans-Peter ;
Hefter, Harald .
NEUROLOGY, 2019, 92 (01) :E48-E54
[3]   EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force [J].
Andersen, Peter M. ;
Abrahams, Sharon ;
Borasio, Gian D. ;
de Carvalho, Mamede ;
Chio, Adriano ;
Van Damme, Philip ;
Hardiman, Orla ;
Kollewe, Katja ;
Morrison, Karen E. ;
Petri, Susanne ;
Pradat, Pierre-Francois ;
Silani, Vincenzo ;
Tomik, Barbara ;
Wasner, Maria ;
Weber, Markus .
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (03) :360-E24
[4]   EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives - An evidence-based review with good practice points [J].
Andersen, PM ;
Borasio, GD ;
Dengler, R ;
Hardiman, O ;
Kollewe, K ;
Leigh, PN ;
Pradat, PF ;
Silani, V ;
Tomik, B .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (12) :921-938
[5]  
[Anonymous], 2011, DYSPH DIET FOOD TEXT
[6]   Glycopyrrolate for sialorrhea in Parkinson disease A randomized, double-blind, crossover trial [J].
Arbouw, M. E. L. ;
Movig, K. L. L. ;
Koopmann, M. ;
Poels, P. J. E. ;
Guchelaar, H. -J. ;
Egberts, T. C. G. ;
Neef, C. ;
van Vugt, J. P. P. .
NEUROLOGY, 2010, 74 (15) :1203-1207
[7]   The natural history of motor neuron disease: Assessing the impact of specialist care [J].
Aridegbe, Tomi ;
Kandler, Rosalind ;
Walters, Stephen J. ;
Walsh, Theresa ;
Shaw, Pamela J. ;
McDermott, Christopher J. .
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2013, 14 (01) :13-19
[8]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[9]   Radiation Therapy for Hypersalivation: A Prospective Study in 50 Amyotrophic Lateral Sclerosis Patients [J].
Assouline, Avi ;
Levy, Antonin ;
Abdelnour-Mallet, Maya ;
Gonzalez-Bermejo, Jesus ;
Lenglet, Timothee ;
Le Forestier, Nadine ;
Salachas, Francois ;
Bruneteau, Gaelle ;
Meininger, Vincent ;
Delanian, Sylvie ;
Pradat, Pierre-Francois .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (03) :589-595
[10]   Understanding mealtime changes for adults with cerebral palsy and the implications for support services [J].
Balandin, Susan ;
Hemsley, Bronwyn ;
Hanley, Leah ;
Sheppard, Justine Joan .
JOURNAL OF INTELLECTUAL & DEVELOPMENTAL DISABILITY, 2009, 34 (03) :197-206